Ozarelix

Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms

... likely increase compliance, while Aeterna Zentaris/Sanofi-Aventis/Shionogi's cetrorelix and Aeterna Zentaris/Spectrum Pharmaceuticals/Nippon Kayaku's ozarelix both aim to reduce the size of the prostate and slow disease progression. Additionally, the report finds that drug developers are also focusing on tar...

AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results

...d our promising drug candidates in oncology, such as AEZS-108 and AEZS-112, while in collaboration with our partners, we expect to move perifosine and ozarelix to the final development stages." Dennis Turpin, Senior Vice President and Chief Financial Officer of AEterna Zentaris added, "The recent partnershi...

Ozarelix in Medical Technology

Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie

... - In Patients With BPH, Clinical Benefit After ozarelix Was Maintained For Up T...study presented today. We continue to believe that ozarelix could help serve the large unmet medical need for ...oups: Group 1: placebo, + placebo Group 2: 5mg ozarelix + 5mg ozarelix; Group 3: 10mg...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

... * ozarelix Effective in Improving Symptoms and Urine Flow, Wi...n the design of the Phase 3 trial. We believe that ozarelix could help serve the large unmet medical need for ...oups: Group 1: placebo, Group 2: 5mg ozarelix on Day 1 + 5mg...

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting

... ozarelix improved LUTS symptoms and urine flow over 28-week...alifornia. "We are encouraged by these data with ozarelix and look forward to seeing further results from th...multi-center, dose-ranging Phase 2 trial in BPH. ozarelix was given intramuscularly (IM) to men with moderat...

Ozarelix in Biological Technology

AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia

QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Spectrum Pharmaceuticals (NASDAQ: SPPI ), released Phase 2b results for ozarelix, a ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...or Use in Late-Stage Prostate Cancer II-62 Protox Gains Clearance from FDA to Conduct Phase I Trial of PRX302 II-63 Aeterna Zentaris's ozarelix Phase II Trial Shows Positive Results II-63 Biomira Announces Results of Stimuvax Phase 2 Clinical Study II-64 Cytogen Receives FDA Clearance ...

AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results

...ls Co., Ltd. (Handok) for the Korean market. Subsequent to quarter end, signing of another agreement with Handok for the commercialization of ozarelix in BPH for the Korean market; and - Recovery of worldwide rights from Ardana plc (LSE: ARA) for the Growth Hormone Secretagogue (GHS) compound, AE...